{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:01:20Z","timestamp":1790910080299,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Zhejiang Provincial Natural Science Foundation of China","award":["LHDMY23H310003"],"award-info":[{"award-number":["LHDMY23H310003"]}]},{"name":"Hospital Pharmaceutical Research Fund Project of Zhejiang Provincial Pharmaceutical Association","award":["[2019ZYY26"],"award-info":[{"award-number":["[2019ZYY26"]}]},{"name":"the Medical and Health Science and Technology Plan Project of Zhejiang Province","award":["2025KY133"],"award-info":[{"award-number":["2025KY133"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00280-025-04799-0","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T06:56:04Z","timestamp":1753944964000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Anti-tumor efficacy of RAF\/MEK inhibitor VS6766 in KRAS-mutated colorectal cancer cells"],"prefix":"10.1007","volume":"95","author":[{"given":"Haixin","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gezi","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youyou","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nengming","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biqin","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,31]]},"reference":[{"key":"4799_CR1","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41571-024-00965-0","volume":"22","author":"P Ciraci","year":"2025","unstructured":"Ciraci P, Studiale V, Taravella A, Antoniotti C, Cremolini C (2025) Late-line options for patients with metastatic colorectal cancer: a review and evidence-based algorithm. Nat Rev Clin Oncol 22:28\u201345. https:\/\/doi.org\/10.1038\/s41571-024-00965-0","journal-title":"Nat Rev Clin Oncol"},{"key":"4799_CR2","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1001\/jamaoncol.2024.5227","volume":"11","author":"MD Knudsen","year":"2025","unstructured":"Knudsen MD, Wang K, Wang L, Polychronidis G, Berstad P, Hjartaker A, Fang Z, Ogino S, Chan AT, Song M (2025) Colorectal cancer incidence and mortality after negative colonoscopy screening results. JAMA Oncol 11:46\u201354. https:\/\/doi.org\/10.1001\/jamaoncol.2024.5227","journal-title":"JAMA Oncol"},{"key":"4799_CR3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jncc.2024.01.006","volume":"4","author":"B Han","year":"2024","unstructured":"Han B, Zheng R, Zeng H, Wang S, Sun K, Chen R, Li L, Wei W, He J (2024) Cancer incidence and mortality in China, 2022. J Natl Cancer Cent 4:47\u201353. https:\/\/doi.org\/10.1016\/j.jncc.2024.01.006","journal-title":"J Natl Cancer Cent"},{"key":"4799_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2024.101152","volume":"77","author":"S Luo","year":"2024","unstructured":"Luo S, Yue M, Wang D, Lu Y, Wu Q, Jiang J (2024) Breaking the barrier: epigenetic strategies to combat platinum resistance in colorectal cancer. Drug Resist Updat 77:101152. https:\/\/doi.org\/10.1016\/j.drup.2024.101152","journal-title":"Drug Resist Updat"},{"key":"4799_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113766","volume":"145","author":"Q Wang","year":"2025","unstructured":"Wang Q, Ma C, Yang B, Zheng W, Liu X, Jian G (2025) Dysregulation of DNA methylation in colorectal cancer: biomarker, immune regulation, and therapeutic potential. Int Immunopharmacol 145:113766. https:\/\/doi.org\/10.1016\/j.intimp.2024.113766","journal-title":"Int Immunopharmacol"},{"key":"4799_CR6","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3892\/mmr.2024.13278","volume":"30","author":"Y Wang","year":"2024","unstructured":"Wang Y, Wang C, Zhong R, Wang L, Sun L (2024) Research progress of DNA methylation in colorectal cancer (Review). Mol Med Rep 30:154. https:\/\/doi.org\/10.3892\/mmr.2024.13278","journal-title":"Mol Med Rep"},{"key":"4799_CR7","doi-asserted-by":"publisher","first-page":"3650","DOI":"10.1200\/JCO.2015.62.1052","volume":"33","author":"H Singh","year":"2015","unstructured":"Singh H, Longo DL, Chabner BA (2015) Improving prospects for targeting RAS. J Clin Oncol 33:3650\u20133659. https:\/\/doi.org\/10.1200\/JCO.2015.62.1052","journal-title":"J Clin Oncol"},{"key":"4799_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.01.020","author":"JM Riedl","year":"2025","unstructured":"Riedl JM, Fece F, de la Cruz JJ, Lin C, Parseghian JE, Kim H, Matsubara H, Barnes B, Caughey BL, Norden A, Morales EW, Kushner S, Ehnstrom H, Nakamura PS, Patel H, Ellis L, Pappas A, Vakaris JF, Gainor S, Kopetz SJ, Klempner AR, Parikh AN, Hata RS, Heist, Corcoran RB (2025) Genomic landscape of clinically acquired resistance alterations in patients treated with KRAS(G12C) inhibitors. Ann Oncol. https:\/\/doi.org\/10.1016\/j.annonc.2025.01.020","journal-title":"Ann Oncol"},{"key":"4799_CR9","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3892\/mmr.2024.13389","volume":"31","author":"Y Guo","year":"2025","unstructured":"Guo Y, Hu C, Cai K, Long G, Cai D, Yu Z, Huang X, Cai Z, Hu P, Chen Y, Gao F, Wu X (2025) KRAS inhibitors may prevent colorectal cancer metachronous metastasis by suppressing TGF\u2013beta mediated epithelial\u2013mesenchymal transition. Mol Med Rep 31:24. https:\/\/doi.org\/10.3892\/mmr.2024.13389","journal-title":"Mol Med Rep"},{"key":"4799_CR10","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.trecan.2017.08.006","volume":"3","author":"KM Haigis","year":"2017","unstructured":"Haigis KM (2017) KRAS alleles: the devil is in the detail. Trends Cancer 3:686\u2013697. https:\/\/doi.org\/10.1016\/j.trecan.2017.08.006","journal-title":"Trends Cancer"},{"key":"4799_CR11","doi-asserted-by":"publisher","first-page":"4753","DOI":"10.1158\/1078-0432.CCR-17-0400","volume":"23","author":"A Cercek","year":"2017","unstructured":"Cercek A, Braghiroli MI, Chou JF, Hechtman JF, Kemeny N, Saltz L, Capanu M, Yaeger R (2017) Clinical features and outcomes of patients with colorectal cancers harboring NRAS mutations. Clin Cancer Res 23:4753\u20134760. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0400","journal-title":"Clin Cancer Res"},{"key":"4799_CR12","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s12943-021-01441-4","volume":"20","author":"G Zhu","year":"2021","unstructured":"Zhu G, Pei L, Xia H, Tang Q, Bi F (2021) Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer. Mol Cancer 20:143. https:\/\/doi.org\/10.1186\/s12943-021-01441-4","journal-title":"Mol Cancer"},{"key":"4799_CR13","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","volume":"6","author":"L Huang","year":"2021","unstructured":"Huang L, Guo Z, Wang F, Fu L (2021) KRAS mutation: from undruggable to druggable in cancer. Signal Transduct Target Ther 6:386. https:\/\/doi.org\/10.1038\/s41392-021-00780-4","journal-title":"Signal Transduct Target Ther"},{"key":"4799_CR14","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1158\/2159-8290.CD-19-1167","volume":"10","author":"J Hallin","year":"2020","unstructured":"Hallin J, Engstrom LD, Hargis L, Calinisan A, Aranda R, Briere DM, Sudhakar N, Bowcut V, Baer BR, Ballard JA, Burkard MR, Fell JB, Fischer JP, Vigers GP, Xue Y, Gatto S, Fernandez-Banet J, Pavlicek A, Velastagui K, Chao RC, Barton J, Pierobon M, Baldelli E, Patricoin EF, Cassidy DP, Marx MA, Rybkin II, Johnson ML, Ou SI, Lito P, Papadopoulos KP, Janne PA, Olson P, Christensen JG (2020) The KRAS(G12C) inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-Mutant cancers in mouse models and patients. Cancer Discov 10:54\u201371. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-1167","journal-title":"Cancer Discov"},{"key":"4799_CR15","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1101\/gad.352081.124","volume":"39","author":"AD Cox","year":"2025","unstructured":"Cox AD, Der CJ (2025) Undruggable KRAS: druggable after all. Genes Dev 39:132\u2013162. https:\/\/doi.org\/10.1101\/gad.352081.124","journal-title":"Genes Dev"},{"key":"4799_CR16","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1016\/S1470-2045(20)30464-2","volume":"21","author":"C Guo","year":"2020","unstructured":"Guo C, Chenard-Poirier M, Roda D, de Miguel M, Harris SJ, Candilejo IM, Sriskandarajah P, Xu W, Scaranti M, Constantinidou A, King J, Parmar M, Turner AJ, Carreira S, Riisnaes R, Finneran L, Hall E, Ishikawa Y, Nakai K, Tunariu N, Basu B, Kaiser M, Lopez JS, Minchom A, de Bono JS, Banerji U (2020) Intermittent schedules of the oral RAF-MEK inhibitor CH5126766\/VS-6766 in patients with RAS\/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study. Lancet Oncol 21:1478\u20131488. https:\/\/doi.org\/10.1016\/S1470-2045(20)30464-2","journal-title":"Lancet Oncol"},{"key":"4799_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2024.117805","volume":"325","author":"LY Han","year":"2024","unstructured":"Han LY, Yu H, Wang S, Bao YR, Li TJ, Zheng Y, Luo X, Jia MN, Zhang Q, Meng XS (2024) Classical prescription floris sophorae powder treat colorectal cancer by regulating KRAS\/MEK-ERK signaling pathway. J Ethnopharmacol 325:117805. https:\/\/doi.org\/10.1016\/j.jep.2024.117805","journal-title":"J Ethnopharmacol"},{"key":"4799_CR18","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41589-024-01683-5","volume":"21","author":"ZQ Peng","year":"2025","unstructured":"Peng ZQ, Fang W, Wu B, He M, Li SH, Wei J, Hao Y, Jin LJ, Liu MQ, Zhang X, Wei YE, Ge YW, Wei YH, Qian HL, Zhang YJ, Jiang JY, Chang ZJ, Rao Y, Zhang XL, Cui CP, Zhang LQ (2025) Targeting Smurf1 to block PDK1-Akt signaling in KRAS-mutated colorectal cancer. Nat Chem Biol 21:59\u201370. https:\/\/doi.org\/10.1038\/s41589-024-01683-5","journal-title":"Nat Chem Biol"},{"key":"4799_CR19","doi-asserted-by":"publisher","first-page":"126","DOI":"10.3892\/mmr.2023.13013","volume":"27","author":"H Xiong","year":"2023","unstructured":"Xiong H, Li Y, Liu MH (2023) DEPDC1B is involved in the proliferation, metastasis, cell cycle arrest and apoptosis of colon cancer cells by regulating NUP37. Mol Med Rep 27:126 Artn 12610.3892\/Mmr.2023.13013","journal-title":"Mol Med Rep"},{"key":"4799_CR20","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.1158\/0008-5472.CAN-22-0198","volume":"82","author":"AV Sorokin","year":"2022","unstructured":"Sorokin AV, Kanikarla Marie P, Bitner L, Syed M, Woods M, Manyam G, Kwong LN, Johnson B, Morris VK, Jones P, Menter DG, Lee MS, Kopetz S (2022) Targeting RAS mutant colorectal cancer with dual inhibition of MEK and CDK4\/6. Cancer Res 82:3335\u20133344. https:\/\/doi.org\/10.1158\/0008-5472.CAN-22-0198","journal-title":"Cancer Res"},{"key":"4799_CR21","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1200\/JCO.19.02654","volume":"38","author":"J Desai","year":"2020","unstructured":"Desai J, Gan H, Barrow C, Jameson M, Atkinson V, Haydon A, Millward M, Begbie S, Brown M, Markman B, Patterson W, Hill A, Horvath L, Nagrial A, Richardson G, Jackson C, Friedlander M, Parente P, Tran B, Wang L, Chen Y, Tang Z, Huang W, Wu J, Zeng D, Luo L, Solomon B (2020) Phase I, open-label, dose-escalation\/dose-expansion study of Lifirafenib (BGB-283), an RAF family kinase inhibitor, in patients with solid tumors. J Clin Oncol 38:2140\u20132150. https:\/\/doi.org\/10.1200\/JCO.19.02654","journal-title":"J Clin Oncol"},{"key":"4799_CR22","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1158\/2326-6066.CIR-23-0729","volume":"12","author":"L Dong","year":"2024","unstructured":"Dong L, Choi H, Budhu S, Schulze I, Verma S, Mangarin LM, Estrada Nevarro V, Mehanna N, Khan JF, Venkatesh D, Thach D, Rosen N, Wolchok JD, Merghoub T (2024) Intermittent MEK Inhibition with GITR costimulation rescues T-cell function for increased efficacy with CTLA-4 Blockade in solid tumor models. Cancer Immunol Res 12:1392\u20131408. https:\/\/doi.org\/10.1158\/2326-6066.CIR-23-0729","journal-title":"Cancer Immunol Res"},{"key":"4799_CR23","doi-asserted-by":"publisher","unstructured":"(2021) Dual RAF-MEK inhibitor assessed. Cancer Discov 11:5\u20136. https:\/\/doi.org\/10.1158\/2159-8290.CD-NB2020-101","DOI":"10.1158\/2159-8290.CD-NB2020-101"},{"key":"4799_CR24","doi-asserted-by":"publisher","first-page":"4050","DOI":"10.1158\/0008-5472.CAN-12-3937","volume":"73","author":"N Ishii","year":"2013","unstructured":"Ishii N, Harada N, Joseph EW, Ohara K, Miura T, Sakamoto H, Matsuda Y, Tomii Y, Tachibana-Kondo Y, Iikura H, Aoki T, Shimma N, Arisawa M, Sowa Y, Poulikakos PI, Rosen N, Aoki Y, Sakai T (2013) Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity. Cancer Res 73:4050\u20134060. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-3937","journal-title":"Cancer Res"},{"key":"4799_CR25","doi-asserted-by":"publisher","first-page":"e70210","DOI":"10.1002\/cam4.70210","volume":"13","author":"TMP Hartwich","year":"2024","unstructured":"Hartwich TMP, Mansolf M, Demirkiran C, Greenman M, Bellone S, McNamara B, Nandi SP, Alexandrov LB, Yang-Hartwich Y, Coma S, Pachter J, Santin AD (2024) Preclinical evaluation of Avutometinib and Defactinib in high-grade endometrioid endometrial cancer. Cancer Med 13:e70210. https:\/\/doi.org\/10.1002\/cam4.70210","journal-title":"Cancer Med"},{"key":"4799_CR26","doi-asserted-by":"publisher","first-page":"4166","DOI":"10.1111\/cas.15071","volume":"112","author":"H Ono","year":"2021","unstructured":"Ono H, Horinaka M, Sukeno M, Morita M, Yasuda S, Nishimoto E, Konishi E, Sakai T (2021) Novel RAF\/MEK inhibitor CH5126766\/VS-6766 has efficacy in combination with eribulin for the treatment of triple-negative breast cancer. Cancer Sci 112:4166\u20134175. https:\/\/doi.org\/10.1111\/cas.15071","journal-title":"Cancer Sci"},{"key":"4799_CR27","doi-asserted-by":"publisher","first-page":"e113217","DOI":"10.1371\/journal.pone.0113217","volume":"9","author":"M Wada","year":"2014","unstructured":"Wada M, Horinaka M, Yamazaki T, Katoh N, Sakai T (2014) The dual RAF\/MEK inhibitor CH5126766\/RO5126766 may be a potential therapy for RAS-mutated tumor cells. PLoS One 9:e113217. https:\/\/doi.org\/10.1371\/journal.pone.0113217","journal-title":"PLoS One"},{"key":"4799_CR28","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ygyno.2024.04.010","volume":"187","author":"C Demirkiran","year":"2024","unstructured":"Demirkiran C, Greenman M, Bellone S, McNamara B, Hartwich TMP, Manavella D, Mutlu L, Zipponi M, Yang-Hartwich Y, Yang K, Ratner E, Schwartz PE, Coma S, Pachter J, Santin AD (2024) Preclinical in vitro and in vivo activity of the RAF\/MEK clamp Avutometinib in combination with FAK inhibition in uterine carcinosarcomas. Gynecol Oncol 187:12\u201320. https:\/\/doi.org\/10.1016\/j.ygyno.2024.04.010","journal-title":"Gynecol Oncol"},{"key":"4799_CR29","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1111\/cas.14414","volume":"111","author":"S Umemura","year":"2020","unstructured":"Umemura S, Sowa Y, Iizumi Y, Kitawaki J, Sakai T (2020) Synergistic effect of the inhibitors of RAF\/MEK and AXL on KRAS-mutated ovarian cancer cells with high AXL expression. Cancer Sci 111:2052\u20132061. https:\/\/doi.org\/10.1111\/cas.14414","journal-title":"Cancer Sci"},{"key":"4799_CR30","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41416-024-02727-2","volume":"131","author":"A Yoshimura","year":"2024","unstructured":"Yoshimura A, Horinaka M, Yaoi T, Ono H, Itoh K, Yamada T, Takayama K, Sakai T (2024) Epithelial-mesenchymal transition status is a remarkable biomarker for the combination treatment with Avutometinib and Defactinib in KRAS-mutated non-small cell lung cancer. Br J Cancer 131:361\u2013371. https:\/\/doi.org\/10.1038\/s41416-024-02727-2","journal-title":"Br J Cancer"},{"key":"4799_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25063304","volume":"25","author":"J Ros","year":"2024","unstructured":"Ros J, Vaghi C, Baraibar I, Saoudi Gonzalez N, Rodriguez-Castells M, Garcia A, Alcaraz A, Salva F, Tabernero J, Elez E (2024) Targeting KRAS G12C mutation in colorectal cancer, a review: new arrows in the quiver. Int J Mol Sci 25:3304. https:\/\/doi.org\/10.3390\/ijms25063304","journal-title":"Int J Mol Sci"},{"key":"4799_CR32","doi-asserted-by":"publisher","first-page":"3455","DOI":"10.3390\/cancers16203455","volume":"16","author":"A Boileve","year":"2024","unstructured":"Boileve A, Smolenschi C, Lambert A, Boige V, Delaye M, Camilleri GM, Tarabay A, Valery M, Fuerea A, Pudlarz T, Mathieu JRR, Jaulin F, Hollebecque A, Ducreux M (2024) KRAS, a New Target for Precision Medicine in Colorectal Cancer? Cancers (Basel) 16:3455. https:\/\/doi.org\/10.3390\/cancers16203455","journal-title":"Cancers (Basel)"},{"key":"4799_CR33","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1080\/14760584.2020.1733420","volume":"19","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Ma JA, Zhang HX, Jiang YN, Luo WH (2020) Cancer vaccines: targeting KRAS-driven cancers. Expert Rev Vaccines 19:163\u2013173. https:\/\/doi.org\/10.1080\/14760584.2020.1733420","journal-title":"Expert Rev Vaccines"},{"issue":"6","key":"4799_CR34","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1053\/j.gastro.2020.08.016","volume":"159","author":"CC Wong","year":"2020","unstructured":"Wong CC, Xu J, Bian X, Wu JL, Kang W, Qian Y, Li W, Chen H, Gou H, Liu D, Yat Luk ST, Zhou Q, Ji F, Chan LS, Shirasawa S, Sung JJ, Yu J (2020) In colorectal cancer cells with mutant KRAS, Slc25a22-mediated glutaminolysis reduces DNA demethylation to increase WNT signaling, stemness, and drug resistance. Gastroenterology 159(6):2163-2180e6. https:\/\/doi.org\/10.1053\/j.gastro.2020.08.016","journal-title":"Gastroenterology"},{"issue":"4","key":"4799_CR35","first-page":"1486","volume":"13","author":"Z Ma","year":"2023","unstructured":"Ma Z, Qi Z, Gu C, Yang Z, Ding Y, Zhou Y, Wang W, Zou Q (2023) BRAFV600E mutation promoted the growth and chemoresistance of colorectal cancer. Am J Cancer Res 13(4):1486\u20131497","journal-title":"Am J Cancer Res"},{"key":"4799_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2015.00116","volume":"6","author":"DM Zocche","year":"2015","unstructured":"Zocche DM, Ramirez C, Fontao FM, Costa LD, Redal MA (2015) Global impact of KRAS mutation patterns in FOLFOX treated metastatic colorectal cancer. Front Genet 6:116. https:\/\/doi.org\/10.3389\/fgene.2015.00116","journal-title":"Front Genet"},{"key":"4799_CR37","doi-asserted-by":"publisher","first-page":"3064","DOI":"10.3390\/cancers15113064","volume":"15","author":"V Formica","year":"2023","unstructured":"Formica V, Morelli C, Conca V, Calegari MA, Lucchetti J, Dell\u2019Aquila E, Schirripa M, Messina M, Salvatore L, Lo Prinzi F, Dima G, Trovato G, Riondino S, Roselli M, Skoulidis F, Arkenau HT, Cremolini C (2023) Irinotecan- vs. Oxaliplatin-Based doublets in KRAS(G12C)-Mutated metastatic colorectal Cancer-A multicentre Propensity-Score-Matched retrospective analysis. Cancers (Basel) 15:3064. https:\/\/doi.org\/10.3390\/cancers15113064","journal-title":"Cancers (Basel)"},{"key":"4799_CR38","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1186\/s12885-023-11253-y","volume":"23","author":"S Putri","year":"2023","unstructured":"Putri S, Saldi SRF, Khoe LC, Setiawan E, Megraini A, Santatiwongchai B, Nugraha RR, Permanasari VY, Nadjib M, Sastroasmoro S, Armansyah A (2023) Cetuximab as first-line treatment for metastatic colorectal cancer (mCRC): a model-based economic evaluation in Indonesia setting. BMC Cancer 23:731. https:\/\/doi.org\/10.1186\/s12885-023-11253-y","journal-title":"BMC Cancer"},{"key":"4799_CR39","doi-asserted-by":"publisher","first-page":"192","DOI":"10.18632\/aging.100296","volume":"3","author":"LS Steelman","year":"2011","unstructured":"Steelman LS, Chappell WH, Abrams SL, Kempf RC, Long J, Laidler P, Mijatovic S, Maksimovic-Ivanic D, Stivala F, Mazzarino MC, Donia M, Fagone P, Malaponte G, Nicoletti F, Libra M, Milella M, Tafuri A, Bonati A, Basecke J, Cocco L, Evangelisti C, Martelli AM, Montalto G, Cervello M, McCubrey JA (2011) Roles of the raf\/mek\/erk and PI3K\/PTEN\/Akt\/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging 3:192\u2013222. https:\/\/doi.org\/10.18632\/aging.100296","journal-title":"Aging"},{"key":"4799_CR40","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s12032-021-01633-4","volume":"39","author":"S Dey","year":"2022","unstructured":"Dey S, Singh AK, Singh AK, Rawat K, Banerjee J, Agnihotri V, Upadhaya D (2022) Critical pathways of oral squamous cell carcinoma: molecular biomarker and therapeutic intervention. Med Oncol 39:30. https:\/\/doi.org\/10.1007\/s12032-021-01633-4","journal-title":"Med Oncol"},{"key":"4799_CR41","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1080\/15384047.2018.1504718","volume":"20","author":"RS Burmi","year":"2019","unstructured":"Burmi RS, Maginn EN, Gabra H, Stronach EA, Wasan HS (2019) Combined inhibition of the PI3K\/mTOR\/MEK pathway induces Bim\/Mcl-1-regulated apoptosis in pancreatic cancer cells. Cancer Biol Ther 20:21\u201330. https:\/\/doi.org\/10.1080\/15384047.2018.1504718","journal-title":"Cancer Biol Ther"},{"key":"4799_CR42","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s43556-022-00110-2","volume":"3","author":"Q Li","year":"2022","unstructured":"Li Q, Li Z, Luo T, Shi H (2022) Targeting the PI3K\/AKT\/mTOR and RAF\/MEK\/ERK pathways for cancer therapy. Mol Biomed 3:47. https:\/\/doi.org\/10.1186\/s43556-022-00110-2","journal-title":"Mol Biomed"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04799-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-025-04799-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04799-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T08:26:59Z","timestamp":1757320019000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-025-04799-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,31]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4799"],"URL":"https:\/\/doi.org\/10.1007\/s00280-025-04799-0","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,31]]},"assertion":[{"value":"23 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"78"}}